Smith & Nephew SNATS (NYSE:SNN) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen lowered shares of Smith & Nephew SNATS (NYSE:SNN) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday morning.

Several other equities analysts have also recently issued reports on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Canaccord Genuity Group raised their price target on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.25.

Smith & Nephew SNATS Price Performance

SNN opened at $31.92 on Friday. Smith & Nephew SNATS has a twelve month low of $23.91 and a twelve month high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. The company has a fifty day simple moving average of $34.36 and a 200 day simple moving average of $34.62.

Smith & Nephew SNATS Announces Dividend

The company also recently announced a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be paid a $0.482 dividend. The ex-dividend date is Friday, March 27th. This represents a yield of 281.0%.

Hedge Funds Weigh In On Smith & Nephew SNATS

Several hedge funds have recently bought and sold shares of the business. River Road Asset Management LLC increased its holdings in shares of Smith & Nephew SNATS by 13.8% during the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock valued at $103,996,000 after acquiring an additional 384,926 shares during the last quarter. NewEdge Advisors LLC increased its position in Smith & Nephew SNATS by 18.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,571 shares of the medical equipment provider’s stock worth $248,000 after acquiring an additional 1,192 shares during the period. XTX Topco Ltd raised its position in shares of Smith & Nephew SNATS by 165.1% during the fourth quarter. XTX Topco Ltd now owns 49,063 shares of the medical equipment provider’s stock valued at $1,610,000 after buying an additional 30,553 shares during the last quarter. Voloridge Investment Management LLC bought a new stake in shares of Smith & Nephew SNATS in the 4th quarter worth approximately $330,000. Finally, OLD Mission Capital LLC bought a new stake in shares of Smith & Nephew SNATS during the fourth quarter valued at approximately $7,438,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.